Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’ TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

Profound Medical Announces Third Quarter 2024 Financial Results TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...

Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch Avricore earned 8th spot in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch list, reflecting its significant growth.

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...